keyword
MENU ▼
Read by QxMD icon Read
search

HPV type 11

keyword
https://www.readbyqxmd.com/read/29020120/hpv-in-women-assisted-by-the-family-health-strategy
#1
Andréia Rodrigues Gonçalves Ayres, Gulnar Azevedo E Silva, Maria Teresa Bustamante Teixeira, Kristiane de Castro Dias Duque, Maria Lúcia Salim Miranda Machado, Carmen Justina Gamarra, José Eduardo Levi
OBJECTIVE: Estimate the prevalence of cervical HPV infection among women assisted by the Family Health Strategy and identify the factors related to the infection. METHODS: A cross-sectional study involving 2,076 women aged 20-59 years old residing in Juiz de Fora, State of Minas Gerais, who were asked to participate in an organized screening carried out in units were the Family Health Strategy had been implemented. Participants answered the standardized questionnaire and underwent a conventional cervical cytology test and HPV test for high oncogenic risk...
October 5, 2017: Revista de Saúde Pública
https://www.readbyqxmd.com/read/29017279/population-level-herd-protection-of-males-from-a-female-human-papillomavirus-vaccination-program-evidence-from-australian-serosurveillance
#2
Alexis J Pillsbury, Helen E Quinn, TaNisha D Evans, Peter B McIntyre, Julia M L Brotherton
Background: Australia instituted funded female human papillomavirus (HPV) immunization in 2007, followed by a targeted male vaccination program in 2013. To date, Australia is one of only several countries with a funded male HPV immunization program. In 2012-2013, we conducted a survey of HPV seroprevalence in males to assess whether or not a herd impact of female vaccination could be observed. Methods: We conducted a cross-sectional study of de-identified residual diagnostic test serum samples from males aged 15-39 years from laboratories in 3 Australian states and calculated the proportion seropositive to HPV types 6, 11, 16, and 18...
September 1, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28983946/human-papillomavirus-type-6-11-identified-in-an-epidermoid-cyst-of-the-scrotum
#3
Masaaki Kawase, Kiyofumi Egawa, Takaoki Ishiji, Hidemi Nakagawa
To date, epidermoid cysts associated with human papillomavirus (HPV) infection have been described mainly in palmoplantar locations, and have involved HPV types 60 and 57. In contrast, HPV-6/11 is a major cause of condyloma acuminatum. Here, we report the case of a healthy 31-year-old man who presented to our clinic with a 1-month history of a 1-cm, reddish-brown, cystic scrotal tumor with a punctum. The lesion was studied histologically, immunohistochemically and by DNA-DNAin situ hybridization. Histology revealed an epidermoid cyst with vacuolated keratinocytes with shrunken nuclei (koilocytes) in the cyst wall...
October 6, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28968993/human-papillomavirus-16l1-58l2-chimeric-virus-like-particles-elicit-durable-neutralizing-antibody-responses-against-a-broad-spectrum-of-human-papillomavirus-types
#4
Xue Chen, Hongyang Liu, Zhirong Wang, Shuo Wang, Ting Zhang, Meili Hu, Liang Qiao, Xuemei Xu
The neutralizing antibodies elicited by human papillomavirus (HPV) major capsid protein L1 virus-like particle (VLP)-based vaccines are largely type-specific. An HPV vaccine inducing cross-neutralizing antibodies broadly will be cost-effective and of great value. To this end, we constructed HPV16L1-58L2 chimeric VLP (cVLP) by displaying HPV58 L2 aa.16-37 on the DE surface region of HPV16 L1. We found that vaccination with the HPV16L1-58L2 cVLP formulated with alum plus monophosphoryl lipid A (Alum-MPL) adjuvant elicited robust neutralizing antibodies in both mice and rabbits against all tested HPV types including HPV16/31/33/35/52/58 (genus α9), HPV18/39/45/59/68 (genus α7), HPV6/11 (genus α10), HPV2/27/57 (genus α4), and HPV5 (genus β1)...
September 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28968844/human-papillomavirus-hpv-prevalence-in-adolescent-males-four-years-post-hpv16-18-vaccination
#5
Tuomas Lehtinen, Anna Söderlund-Strand, Tiina Petäjä, Tiina Eriksson, Sakari Jokiranta, Kari Natunen, Joakim Dillner, Matti Lehtinen
We assessed human papillomavirus (HPV) prevalence among HPV16/18-vaccinated and unvaccinated Finnish males participating to Chlamydia screening 4 years post vaccination with AS04-adjuvanted HPV16/18 vaccine in 2007-2009. Adolescent previously vaccinated (n=395) or unvaccinated (n=149) males were enrolled in 12 municipalities. First void urine samples were tested for HPV types 6/11/16/18/31/33/35/45/51/52/56/58/59/66/68 and for C. trachomatis HPV16/18 and HPV11/16/18/31/33/45 prevalence rates were reduced profoundly (0% vs 2...
August 24, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28968823/naturally-occurring-single-amino-acid-substitution-in-the-l1-major-capsid-protein-of-human-papillomavirus-type-16-alteration-of-susceptibility-to-antibody-mediated-neutralization
#6
Tingting Ning, Aaron Wolfe, Jianhui Nie, Weijin Huang, Xiaojiang S Chen, Youchun Wang
Background: Each vaccine for human papillomavirus type 16 (HPV16) has been developed on the basis of a single variant, and whether these vaccines can prevent infection due to naturally occurring variants was not clear. Methods: To examine this question, constructs of 39 naturally occurring single amino acid substitutions in L1 were generated for pseudovirion production, based on the analysis of 1204 HPV16 L1 protein sequences from the National Center for Biotechnology Information and Papilloma Virus Episteme...
September 2, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28956458/9-valent-human-papillomavirus-vaccine-a-review-of-the-clinical-development-program
#7
Alain Luxembourg, Erin Moeller
The 9-valent human papillomavirus (9vHPV) vaccine covers the same HPV types (6/11/16/18) as the quadrivalent HPV (qHPV) vaccine and 5 additional cancer-causing types (31/33/45/52/58). Epidemiological studies indicate that the 9vHPV vaccine could prevent approximately 90% of cervical cancers, 70-85% of high-grade cervical dysplasia (precancers), 85-95% of HPV-related vulvar, vaginal, and anal cancers, and 90% of genital warts. Areas covered: Study design features and key findings from the 9vHPV vaccine clinical development program are reviewed...
October 9, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28954299/durability-of-protection-afforded-by-fewer-doses-of-the-hpv16-18-vaccine-the-cvt-trial
#8
RANDOMIZED CONTROLLED TRIAL
Mahboobeh Safaeian, Joshua N Sampson, Yuanji Pan, Carolina Porras, Troy J Kemp, Rolando Herrero, Wim Quint, Leen Jan van Doorn, John Schussler, Douglas R Lowy, John Schiller, Mark T Schiffman, Ana Cecilia Rodriguez, Mitchell H Gail, Allan Hildesheim, Paula Gonzalez, Ligia A Pinto, Aimée R Kreimer
Background: Previously, we demonstrated similar human papillomavirus (HPV)16/18 vaccine efficacy estimates and stable HPV16/18 antibody levels four years postvaccination in a nonrandomized analysis of women who received a varying number of doses of the bivalent HPV16/18 vaccine. Here we extend data to seven years following initial vaccination. Methods: We evaluated HPV16/18-vaccinated women who received one (n = 134), two (n 0/1 = 193, n 0/6 = 79), or three doses (n = 2043) to a median of 6...
February 1, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28950841/self-collected-vaginal-sampling-for-the-detection-of-genital-human-papillomavirus-hpv-using-carehpv-among-ghanaian-women
#9
Dorcas Obiri-Yeboah, Yaw Adu-Sarkodie, Florencia Djigma, Anna Hayfron-Benjamin, Latif Abdul, Jacques Simpore, Philippe Mayaud
BACKGROUND: Detection of genital HPV DNA is recommended as an important strategy for modern cervical cancer screening. Challenges include access to services, the reliance on cervical samples taken by clinicians, and patient's preference regarding provider gender. The objective of this research was to determine the acceptability, feasibility and performance of alternative self-collected vaginal samples for HPV detection among Ghanaian women. METHODS: A comparative frequency-matched study was conducted in a systematic (1:5) sample of women attending HIV and outpatient clinics in the Cape Coast Teaching Hospital, Ghana...
September 26, 2017: BMC Women's Health
https://www.readbyqxmd.com/read/28943220/who-s-not-protected-in-the-herd-factors-associated-with-vaccine-type-hpv-in-unvaccinated-women
#10
C Smith, L Ding, P M Gorbach, E L Franco, J A Kahn
STUDY OBJECTIVE: Evidence suggests that vaccine-type human papillomavirus (HPV) prevalence may decrease in unvaccinated women after HPV vaccine introduction, indicating herd protection. The aim of this study was to determine factors associated with vaccine-type HPV (i.e. absence of herd protection) after vaccine introduction. DESIGN: We conducted three cross-sectional studies from 2006-2014 (n=1180): wave 1 (2006-2007), wave 2 (2009-2010), and wave 3 (2013-2014)...
September 21, 2017: Journal of Pediatric and Adolescent Gynecology
https://www.readbyqxmd.com/read/28931217/prevalence-of-human-papillomavirus-among-females-after-vaccine-introduction-national-health-and-nutrition-examination-survey-united-states-2003-2014
#11
Sara E Oliver, Elizabeth R Unger, Rayleen Lewis, Darius McDaniel, Julia W Gargano, Martin Steinau, Lauri E Markowitz
Background: Human papillomavirus (HPV) vaccine was recommended in 2006 for routine vaccination of US females aged 11-12 years. Most vaccine used through 2014 was quadrivalent vaccine (4vHPV), which prevents HPV-6, -11, -16, and -18 infection. To evaluate vaccine impact, we measured HPV prevalence in the National Health and Nutrition Examination Survey (NHANES). Methods: We analyzed HPV DNA types detected in self-collected cervicovaginal specimens and demographic, sexual behavior, and self-reported vaccination data from females 14-34 years old...
September 1, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28926579/cervical-screening-with-primary-hpv-testing-or-cytology-in-a-population-of-women-in-which-those-aged-33-years-or-younger-had-previously-been-offered-hpv-vaccination-results-of-the-compass-pilot-randomised-trial
#12
RANDOMIZED CONTROLLED TRIAL
Karen Canfell, Michael Caruana, Val Gebski, Jessica Darlington-Brown, Stella Heley, Julia Brotherton, Dorota Gertig, Chloe J Jennett, Annabelle Farnsworth, Jeffrey Tan, C David Wrede, Philip E Castle, Marion Saville
BACKGROUND: Using primary human papillomavirus (HPV) testing for cervical screening increases detection of high-grade cervical intraepithelial neoplastic lesions and invasive cancer (cervical intraepithelial neoplasia grade 2+ [CIN2+]) compared to cytology, but no evaluation has been conducted in a population previously offered HPV vaccination. We aimed to assess colposcopy referral and CIN2+ detection rates for HPV-screened versus cytology-screened women in Australia's HPV-vaccinated population (by 2014, resident women ≤33 years had been age-eligible for HPV vaccination, with 3-dose uptake across age cohorts being about 50%-77%)...
September 2017: PLoS Medicine
https://www.readbyqxmd.com/read/28913693/human-papillomavirus-genotype-distribution-in-cervical-samples-among-vaccine-na%C3%A3-ve-barbados-women
#13
Juann M Ward, Kolin Schmalenberg, Nick A Antonishyn, Ian R Hambleton, Elizabeth L Blackman, Paul N Levett, Marquita V Gittens-St Hilaire
PURPOSE: This study was undertaken to provide baseline HPV genotype distribution among women in Barbados before HPV immunization was introduced. This information would then be used as a denominator for post-vaccine surveillance and is expected to aid in understanding the effect of vaccination on cervical disease in Barbados. METHODS: Liquid-based cytology specimens were collected from 413 women (age range 18-65 years) attending three clinics, in a pre-vaccination, population-based study...
September 14, 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/28899625/cost-effectiveness-of-hpv-vaccination-in-the-context-of-high-cervical-cancer-incidence-and-low-screening-coverage
#14
Triin Võrno, Katrin Lutsar, Anneli Uusküla, Lee Padrik, Terje Raud, Rainer Reile, Oliver Nahkur, Raul-Allan Kiivet
BACKGROUND: Estonia has high cervical cancer incidence and low screening coverage. We modelled the impact of population-based bivalent, quadrivalent or nonavalent HPV vaccination alongside cervical cancer screening. METHODS: A Markov cohort model of the natural history of HPV infection was used to assess the cost-effectiveness of vaccinating a cohort of 12-year-old girls with bivalent, quadrivalent or nonavalent vaccine in two doses in a national, school-based vaccination programme...
November 1, 2017: Vaccine
https://www.readbyqxmd.com/read/28894838/recurrent-respiratory-papillomatosis-rrp-time-for-a-reckoning
#15
Peter Kin Cho Goon, Lars-Uwe Scholtz, Holger Sudhoff
OBJECTIVES: Recurrent respiratory papillomatosis (RRP) is a rare disease, but one with severe morbidity and occasional mortality. The aetiological agent is human papillomavirus (HPV), and HPV types 6 and 11 account for over 90% of all cases. In the active phase of the disease, patients require multiple hospital admissions for surgical removal or ablation of these benign tumors, which are likely to obstruct the airways if left unchecked. Long-term sequelae include scarring of the vocal cords, change in voice timbre, or even muteness if a tracheostomy is required...
August 2017: Laryngoscope Investigative Otolaryngology
https://www.readbyqxmd.com/read/28881043/human-papillomavirus-prevalence-in-lung-carcinomas-in-bulgaria
#16
Evelina Shikova, Zina Ivanova, Dora Alexandrova, Mihail Shindov, Andrey Lekov
A possible association between high-risk human papillomaviruses (HPV) and lung cancer has been investigated for decades with discrepant results. The aim of this study was to determine the prevalence of HPV16 and 18 in Bulgarian patients with lung cancer. Two hundred and nine biopsy specimens from patients with histologically proven lung cancer and without cancer were analyzed. Each sample was subjected to three parallel PCRs using broad spectrum GP5+/6+ primers and type-specific (TS) primers for HPV types 16 and 18...
October 2017: Microbiology and Immunology
https://www.readbyqxmd.com/read/28877828/infection-modes-and-subtypes-of-human-papilloma-virus-in-patients
#17
Rui Zhang, Xin-Xing Bi, Ali Ye, Ling-Jun Kong, Ya-Ling Dou
Objective To investigate the prevalence of human papilloma virus(HPV)subtypes in patients and to provide an evidence for the prevention and treatment of HPV infection and the development of HPV vaccine. Methods Multiplex PCR was used to detect HPV DNA in 6917 patients in Peking Union Medical College Hospital from January 1,2013 to June 30,2015.Totally 5586 patients entered the final analysis after the repeat samples were deleted.The total positive rate of HPV subtypes(including high-risk subtypes including HPV-16,18,31,33,35,39,45,51,52,56,58,59,and 68 and low-risk subtypes including HPV-6 and 11)and the infection status of different age were analyzed...
August 20, 2017: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
https://www.readbyqxmd.com/read/28855937/immunization-of-mice-by-a-multimeric-l2-based-linear-epitope-17-36-from-hpv-type-16-18-induced-cross-reactive-neutralizing-antibodies
#18
Farhad Motavalli Khiavi, Arash Arashkia, Maryam Nasimi, Mehdi Mahdavi, Majid Golkar, Farzin Roohvand, Kayhan Azadmanesh
Current licensed and commercially available prophylactic human papillomavirus (HPV) vaccines (Cervarix and quadrivalent/nine valents Gardasil) are based on major capsid protein L1 virus-like particles (VLPs) production which are expensive and type specific. Minor capsid L2-RG1 linear epitope (17-36) is a known candidate for induction of cross-neutralizing antibodies to develop low-cost pan-HPV vaccines. Herein, we report construction and expression of a three tandem repeats of L2-RG1 derived from HPV16 and 18 fused with the same head to tail pattern (HPV16:17-36×3+ HPV18:17-36×3; hereafter termed dual-type fusion L2 peptide) in E...
August 2017: Research in Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28832285/prevalence-of-anogenital-hpv-infection-related-disease-and-risk-factors-among-hiv-infected-men-in-inner-city-johannesburg-south-africa-baseline-findings-from-a-cohort-study
#19
Admire Chikandiwa, Lucy Chimoyi, Pedro T Pisa, Matthew F Chersich, Etienne E Muller, Pamela Michelow, Philippe Mayaud, Sinead Delany-Moretlwe
BACKGROUND: Persistent high-risk human papillomavirus (HR-HPV) infection is associated with the development of anogenital cancers, particularly in men living with HIV (MLWH). We describe the prevalence of anogenital HPV infection, abnormal anal cytology and anogenital warts (AGWs) in MLWH in Johannesburg, and explore whether HPV infection and receipt of antiretroviral treatment is associated with detection of abnormal anal cytology and AGWs. METHODS: We enrolled a cohort of 304 sexually-active MLWH ≥18 years, who completed a questionnaire and physical examination...
July 4, 2017: BMC Public Health
https://www.readbyqxmd.com/read/28799537/hpv-16-in-a-distinct-subset-of-oral-epithelial-dysplasia
#20
Mark A Lerman, Soulafa Almazrooa, Neal Lindeman, Dimity Hall, Alessandro Villa, Sook-Bin Woo
Human papillomavirus (HPV) 16 is the most common high-risk HPV type identified in oropharyngeal and cervical neoplasia. Recently, HPV-associated oral epithelial dysplasia with specific histopathologic features and demographics similar to HPV-oropharyngeal carcinoma has been identified. The objective of this study was to evaluate histopathologically all cases of HPV-oral epithelial dysplasia seen in one center and identify HPV types in a subset of cases. Cases with specific histopathology for HPV-oral epithelial dysplasia that were positive both by immunohistochemical studies for p16 and by in situ hybridization for high-risk types of HPV were further analyzed using QIAamp DNA Tissue Kits (Qiagen, Hilden, Germany)...
August 11, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
keyword
keyword
99301
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"